Filing Details

Accession Number:
0001209191-13-057203
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-12-16 19:13:24
Reporting Period:
2013-12-13
Filing Date:
2013-12-16
Accepted Time:
2013-12-16 19:13:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949699 Pharmacyclics Inc PCYC Pharmaceutical Preparations (2834) 943148201
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1455767 M Rainer Erdtmann C/O Pharmacyclics, Inc.
995 East Arques Avenue
Sunnyvale CA 94085
Sr. Vp, Ir And Admin No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-12-13 31,165 $0.91 42,662 No 4 M Direct
Common Stock Disposition 2013-12-13 31,165 $107.82 11,497 No 4 S Direct
Common Stock Acquisiton 2013-12-16 22,835 $0.91 34,332 No 4 M Direct
Common Stock Disposition 2013-12-16 22,835 $107.72 11,497 No 4 S Direct
Common Stock Disposition 2013-12-16 6,000 $0.00 5,497 No 5 G Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 5 G Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-12-13 31,165 $0.00 31,165 $0.91
Common Stock Stock Option (Right to Buy) Disposition 2013-12-16 22,835 $0.00 22,835 $0.91
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
174,835 2009-02-05 2019-02-05 No 4 M Direct
152,000 2009-02-05 2019-02-05 No 4 M Direct
Footnotes
  1. The shares subject to the option will vest as follows: 50,000 shares subject to the option will vest on February 5, 2010 and the remaining shares will vest subject to the attainment of certain corporate events. Such vesting is subject to the Reporting Person's continued employment or service relationshipment with the Issuer on each of the vesting dates.